| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liability, Legal | 8 | 2025 | 50 | 3.950 |
Why?
|
| Neurologists | 9 | 2025 | 27 | 3.180 |
Why?
|
| Malpractice | 5 | 2025 | 60 | 3.110 |
Why?
|
| Neurology | 5 | 2025 | 118 | 2.240 |
Why?
|
| Medicare | 3 | 2023 | 447 | 1.750 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 4 | 2019 | 277 | 1.070 |
Why?
|
| Nervous System Diseases | 5 | 2016 | 412 | 0.970 |
Why?
|
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 4 | 2018 | 35 | 0.890 |
Why?
|
| United States Food and Drug Administration | 3 | 2022 | 160 | 0.870 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2023 | 21 | 0.810 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2021 | 121 | 0.770 |
Why?
|
| Chronic Pain | 1 | 2024 | 148 | 0.750 |
Why?
|
| Physicians | 2 | 2019 | 640 | 0.740 |
Why?
|
| Glioblastoma | 2 | 2018 | 374 | 0.720 |
Why?
|
| Brain Death | 1 | 2022 | 70 | 0.700 |
Why?
|
| Confidentiality | 2 | 2023 | 106 | 0.690 |
Why?
|
| Social Media | 1 | 2023 | 120 | 0.680 |
Why?
|
| Terminal Care | 2 | 2019 | 120 | 0.680 |
Why?
|
| Medicaid | 1 | 2023 | 248 | 0.670 |
Why?
|
| Antipsychotic Agents | 3 | 2019 | 381 | 0.670 |
Why?
|
| Criminal Law | 1 | 2020 | 14 | 0.670 |
Why?
|
| REM Sleep Behavior Disorder | 1 | 2020 | 17 | 0.660 |
Why?
|
| Homicide | 1 | 2020 | 35 | 0.650 |
Why?
|
| Third-Party Consent | 1 | 2020 | 28 | 0.650 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 471 | 0.630 |
Why?
|
| Humans | 56 | 2025 | 132247 | 0.610 |
Why?
|
| Bioethical Issues | 1 | 2019 | 23 | 0.610 |
Why?
|
| Standard of Care | 1 | 2020 | 134 | 0.610 |
Why?
|
| Drug Labeling | 1 | 2019 | 30 | 0.590 |
Why?
|
| Automobile Driving | 1 | 2019 | 34 | 0.590 |
Why?
|
| Group Practice | 1 | 2018 | 12 | 0.580 |
Why?
|
| Brain Neoplasms | 2 | 2018 | 1410 | 0.570 |
Why?
|
| Fibrinolytic Agents | 1 | 2020 | 207 | 0.570 |
Why?
|
| Thrombolytic Therapy | 1 | 2020 | 216 | 0.570 |
Why?
|
| United States | 11 | 2025 | 11669 | 0.570 |
Why?
|
| Herpesvirus 3, Human | 1 | 2018 | 30 | 0.560 |
Why?
|
| Interferon beta-1a | 1 | 2017 | 20 | 0.560 |
Why?
|
| Referral and Consultation | 1 | 2021 | 570 | 0.550 |
Why?
|
| Alzheimer Disease | 2 | 2022 | 866 | 0.550 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 1 | 2017 | 42 | 0.540 |
Why?
|
| Disclosure | 1 | 2018 | 153 | 0.540 |
Why?
|
| Legislation as Topic | 1 | 2017 | 5 | 0.540 |
Why?
|
| United States Dept. of Health and Human Services | 1 | 2017 | 5 | 0.540 |
Why?
|
| Drug Eruptions | 2 | 2016 | 34 | 0.520 |
Why?
|
| Computer Security | 1 | 2017 | 28 | 0.520 |
Why?
|
| Investments | 1 | 2016 | 12 | 0.510 |
Why?
|
| Private Sector | 1 | 2016 | 26 | 0.510 |
Why?
|
| Fraud | 3 | 2023 | 16 | 0.510 |
Why?
|
| Health Policy | 1 | 2019 | 232 | 0.510 |
Why?
|
| Dermatologic Agents | 1 | 2016 | 30 | 0.510 |
Why?
|
| Ownership | 1 | 2016 | 35 | 0.500 |
Why?
|
| Compensation and Redress | 1 | 2016 | 12 | 0.490 |
Why?
|
| Central Nervous System Agents | 1 | 2016 | 15 | 0.490 |
Why?
|
| Negotiating | 1 | 2016 | 12 | 0.490 |
Why?
|
| Expert Testimony | 1 | 2016 | 36 | 0.490 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 462 | 0.490 |
Why?
|
| Morals | 1 | 2016 | 73 | 0.470 |
Why?
|
| Ambulatory Care Facilities | 2 | 2016 | 241 | 0.450 |
Why?
|
| Truth Disclosure | 1 | 2016 | 105 | 0.450 |
Why?
|
| Mental Disorders | 2 | 2014 | 893 | 0.440 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 261 | 0.440 |
Why?
|
| Lymphoma | 1 | 2017 | 331 | 0.430 |
Why?
|
| Patient Safety | 1 | 2019 | 442 | 0.430 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2013 | 20 | 0.420 |
Why?
|
| Dementia | 1 | 2019 | 475 | 0.410 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2013 | 11 | 0.410 |
Why?
|
| Decision Making | 1 | 2018 | 699 | 0.400 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2014 | 64 | 0.390 |
Why?
|
| Epilepsy | 2 | 2019 | 891 | 0.390 |
Why?
|
| Magnetic Resonance Imaging | 8 | 2013 | 3853 | 0.390 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 137 | 0.380 |
Why?
|
| Brain Infarction | 1 | 2012 | 30 | 0.380 |
Why?
|
| Autoantibodies | 3 | 2017 | 458 | 0.380 |
Why?
|
| Anti-Retroviral Agents | 1 | 2014 | 150 | 0.380 |
Why?
|
| Cerebral Hemorrhage | 1 | 2013 | 158 | 0.380 |
Why?
|
| Corpus Callosum | 1 | 2012 | 104 | 0.370 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2017 | 149 | 0.370 |
Why?
|
| Scleroderma, Systemic | 1 | 2013 | 125 | 0.360 |
Why?
|
| Stroke | 1 | 2020 | 1082 | 0.360 |
Why?
|
| Limbic Encephalitis | 1 | 2011 | 4 | 0.350 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2011 | 75 | 0.340 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2011 | 18 | 0.340 |
Why?
|
| Toxoplasmosis | 1 | 2011 | 22 | 0.340 |
Why?
|
| Neurocysticercosis | 2 | 2011 | 27 | 0.340 |
Why?
|
| Sneddon Syndrome | 1 | 2010 | 3 | 0.330 |
Why?
|
| Immunologic Factors | 2 | 2014 | 185 | 0.330 |
Why?
|
| Peripheral Nervous System | 1 | 2010 | 44 | 0.330 |
Why?
|
| Pelvic Floor | 1 | 2010 | 39 | 0.330 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2011 | 138 | 0.320 |
Why?
|
| Biomarkers | 2 | 2022 | 3404 | 0.320 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2011 | 236 | 0.300 |
Why?
|
| Isaacs Syndrome | 1 | 2008 | 2 | 0.290 |
Why?
|
| Central Nervous System | 1 | 2010 | 283 | 0.290 |
Why?
|
| Antitubercular Agents | 1 | 2010 | 263 | 0.290 |
Why?
|
| Cyclophosphamide | 1 | 2010 | 426 | 0.280 |
Why?
|
| Electromyography | 1 | 2008 | 140 | 0.270 |
Why?
|
| Emotions | 1 | 2010 | 367 | 0.270 |
Why?
|
| Middle Aged | 12 | 2021 | 29021 | 0.260 |
Why?
|
| Memory | 1 | 2010 | 356 | 0.260 |
Why?
|
| HIV Infections | 1 | 2018 | 2050 | 0.250 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 673 | 0.240 |
Why?
|
| Female | 22 | 2022 | 70785 | 0.240 |
Why?
|
| Male | 18 | 2021 | 65012 | 0.230 |
Why?
|
| Fatal Outcome | 4 | 2017 | 376 | 0.230 |
Why?
|
| Burnout, Professional | 2 | 2017 | 132 | 0.230 |
Why?
|
| State Government | 1 | 2024 | 30 | 0.220 |
Why?
|
| Tuberculosis | 1 | 2010 | 556 | 0.210 |
Why?
|
| Brain Diseases | 1 | 2006 | 308 | 0.210 |
Why?
|
| Privacy | 1 | 2023 | 28 | 0.200 |
Why?
|
| Adult | 14 | 2018 | 31614 | 0.200 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2021 | 2166 | 0.200 |
Why?
|
| Drug Prescriptions | 1 | 2024 | 239 | 0.190 |
Why?
|
| Informed Consent | 1 | 2025 | 346 | 0.190 |
Why?
|
| Prescriptions | 1 | 2022 | 44 | 0.190 |
Why?
|
| Computer Communication Networks | 1 | 2022 | 16 | 0.180 |
Why?
|
| Palliative Care | 2 | 2019 | 456 | 0.180 |
Why?
|
| Chlorpromazine | 1 | 2001 | 12 | 0.180 |
Why?
|
| Critical Care | 2 | 2020 | 687 | 0.180 |
Why?
|
| Hyperpigmentation | 1 | 2001 | 13 | 0.180 |
Why?
|
| Emergency Medical Services | 2 | 2021 | 416 | 0.180 |
Why?
|
| Immunoglobulins, Intravenous | 2 | 2014 | 150 | 0.180 |
Why?
|
| Mobile Health Units | 1 | 2021 | 26 | 0.180 |
Why?
|
| Physician Self-Referral | 1 | 2021 | 1 | 0.180 |
Why?
|
| Ambulances | 1 | 2021 | 22 | 0.180 |
Why?
|
| Cerebral Angiography | 2 | 2013 | 107 | 0.180 |
Why?
|
| International Cooperation | 1 | 2022 | 167 | 0.170 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2012 | 165 | 0.170 |
Why?
|
| Aphasia | 1 | 2020 | 14 | 0.160 |
Why?
|
| Dopamine D2 Receptor Antagonists | 1 | 2019 | 6 | 0.160 |
Why?
|
| Spouses | 1 | 2020 | 73 | 0.160 |
Why?
|
| Metoclopramide | 1 | 2019 | 11 | 0.160 |
Why?
|
| Job Satisfaction | 2 | 2017 | 99 | 0.160 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 211 | 0.160 |
Why?
|
| Tardive Dyskinesia | 1 | 2019 | 13 | 0.150 |
Why?
|
| Ethics, Medical | 1 | 2022 | 401 | 0.150 |
Why?
|
| Internet | 1 | 2021 | 406 | 0.150 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 767 | 0.140 |
Why?
|
| Fetus | 1 | 2022 | 590 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2021 | 447 | 0.140 |
Why?
|
| Brain Injuries | 2 | 2016 | 716 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2017 | 66 | 0.130 |
Why?
|
| Counseling | 1 | 2019 | 233 | 0.130 |
Why?
|
| Aged | 6 | 2022 | 21482 | 0.130 |
Why?
|
| Healthcare Financing | 1 | 2016 | 6 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 299 | 0.130 |
Why?
|
| Teratoma | 1 | 2017 | 129 | 0.130 |
Why?
|
| Civil Rights | 1 | 2016 | 10 | 0.120 |
Why?
|
| History, Medieval | 1 | 2016 | 28 | 0.120 |
Why?
|
| Unconsciousness | 1 | 2016 | 18 | 0.120 |
Why?
|
| History, Ancient | 1 | 2016 | 56 | 0.120 |
Why?
|
| Virtues | 1 | 2016 | 21 | 0.120 |
Why?
|
| Ethical Analysis | 1 | 2016 | 48 | 0.120 |
Why?
|
| Beneficence | 1 | 2016 | 84 | 0.120 |
Why?
|
| Graves Disease | 1 | 2015 | 13 | 0.120 |
Why?
|
| Hyperthyroidism | 1 | 2015 | 24 | 0.120 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 379 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 390 | 0.110 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 196 | 0.110 |
Why?
|
| Diagnosis, Differential | 2 | 2017 | 1966 | 0.110 |
Why?
|
| Cytokines | 1 | 2020 | 1365 | 0.110 |
Why?
|
| Cognition Disorders | 1 | 2018 | 571 | 0.110 |
Why?
|
| Injections, Intravenous | 2 | 2014 | 247 | 0.110 |
Why?
|
| Polyradiculoneuropathy | 1 | 2013 | 6 | 0.100 |
Why?
|
| Occipital Lobe | 1 | 2013 | 34 | 0.100 |
Why?
|
| Psychotic Disorders | 1 | 2015 | 150 | 0.100 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2014 | 92 | 0.100 |
Why?
|
| Treatment Outcome | 4 | 2015 | 13027 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2017 | 462 | 0.100 |
Why?
|
| Time Factors | 2 | 2020 | 6451 | 0.100 |
Why?
|
| Pregnancy | 3 | 2022 | 7557 | 0.100 |
Why?
|
| Plasma Exchange | 1 | 2014 | 88 | 0.100 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2017 | 496 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 3093 | 0.090 |
Why?
|
| Laminectomy | 1 | 2011 | 24 | 0.090 |
Why?
|
| Glucocorticoids | 1 | 2014 | 387 | 0.090 |
Why?
|
| Neurologic Examination | 1 | 2011 | 202 | 0.090 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2011 | 63 | 0.090 |
Why?
|
| Respiration, Artificial | 1 | 2014 | 504 | 0.090 |
Why?
|
| Electroencephalography | 2 | 2013 | 908 | 0.080 |
Why?
|
| Benzodiazepines | 1 | 2011 | 108 | 0.080 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2017 | 1348 | 0.080 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2010 | 13 | 0.080 |
Why?
|
| Pregnancy Complications | 1 | 2015 | 551 | 0.080 |
Why?
|
| Verbal Learning | 1 | 2010 | 71 | 0.080 |
Why?
|
| Rituximab | 1 | 2011 | 167 | 0.080 |
Why?
|
| Williams Syndrome | 1 | 2009 | 41 | 0.080 |
Why?
|
| Young Adult | 3 | 2014 | 9966 | 0.080 |
Why?
|
| Social Perception | 1 | 2009 | 56 | 0.080 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 270 | 0.080 |
Why?
|
| Amygdala | 1 | 2009 | 85 | 0.080 |
Why?
|
| Executive Function | 1 | 2010 | 127 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 1161 | 0.080 |
Why?
|
| Neurosurgical Procedures | 1 | 2011 | 317 | 0.070 |
Why?
|
| Skin Diseases | 1 | 2010 | 136 | 0.070 |
Why?
|
| Attention | 1 | 2010 | 200 | 0.070 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2010 | 294 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 1294 | 0.070 |
Why?
|
| Lumbosacral Region | 1 | 2007 | 25 | 0.070 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2007 | 17 | 0.070 |
Why?
|
| Rehabilitation | 1 | 2007 | 23 | 0.070 |
Why?
|
| Depersonalization | 2 | 2017 | 10 | 0.070 |
Why?
|
| Electrophysiology | 1 | 2008 | 268 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1134 | 0.070 |
Why?
|
| Physical and Rehabilitation Medicine | 1 | 2007 | 37 | 0.070 |
Why?
|
| Learning | 1 | 2010 | 370 | 0.060 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2010 | 413 | 0.060 |
Why?
|
| Neuropsychological Tests | 1 | 2010 | 990 | 0.060 |
Why?
|
| Disasters | 1 | 2007 | 106 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 5410 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2011 | 1304 | 0.060 |
Why?
|
| Muscle, Skeletal | 1 | 2010 | 1037 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2021 | 1255 | 0.050 |
Why?
|
| Schools, Medical | 1 | 2024 | 122 | 0.050 |
Why?
|
| Animals | 2 | 2016 | 34850 | 0.050 |
Why?
|
| Antineoplastic Agents | 1 | 2011 | 1829 | 0.050 |
Why?
|
| Tobramycin | 1 | 2001 | 22 | 0.040 |
Why?
|
| Piperacillin | 1 | 2001 | 14 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 106 | 0.040 |
Why?
|
| Erythema | 1 | 2001 | 29 | 0.040 |
Why?
|
| Faculty, Medical | 1 | 2024 | 277 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2001 | 66 | 0.040 |
Why?
|
| CD4-CD8 Ratio | 1 | 2020 | 13 | 0.040 |
Why?
|
| Disability Evaluation | 1 | 2021 | 198 | 0.040 |
Why?
|
| Penicillins | 1 | 2001 | 155 | 0.040 |
Why?
|
| Education, Medical | 1 | 2024 | 302 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2020 | 55 | 0.040 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2020 | 27 | 0.040 |
Why?
|
| Netherlands | 1 | 2019 | 47 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 765 | 0.040 |
Why?
|
| Anti-Infective Agents | 1 | 2001 | 270 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 305 | 0.040 |
Why?
|
| Interleukin-6 | 1 | 2020 | 435 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 308 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 337 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 306 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2020 | 449 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2020 | 503 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 526 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 811 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 1354 | 0.030 |
Why?
|
| Critical Illness | 1 | 2020 | 618 | 0.030 |
Why?
|
| Fatigue | 1 | 2017 | 201 | 0.030 |
Why?
|
| Personal Autonomy | 1 | 2017 | 205 | 0.030 |
Why?
|
| Thrombosis | 1 | 2020 | 528 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2019 | 778 | 0.030 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 333 | 0.030 |
Why?
|
| Cerebrospinal Fluid | 1 | 2014 | 98 | 0.030 |
Why?
|
| Hydrolases | 1 | 2013 | 61 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1444 | 0.030 |
Why?
|
| Autoantigens | 1 | 2013 | 109 | 0.020 |
Why?
|
| Adolescent | 2 | 2008 | 20557 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1186 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2022 | 5176 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2013 | 258 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 725 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1671 | 0.020 |
Why?
|
| Age Factors | 1 | 2017 | 2923 | 0.020 |
Why?
|
| Prevalence | 1 | 2017 | 2664 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2011 | 437 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2011 | 588 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2001 | 2552 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2009 | 277 | 0.020 |
Why?
|
| Self Concept | 1 | 2009 | 164 | 0.020 |
Why?
|
| Social Behavior | 1 | 2009 | 225 | 0.020 |
Why?
|
| Skin Ulcer | 1 | 2007 | 32 | 0.020 |
Why?
|
| Louisiana | 1 | 2007 | 136 | 0.020 |
Why?
|
| Disaster Planning | 1 | 2007 | 62 | 0.020 |
Why?
|
| Musculoskeletal Diseases | 1 | 2007 | 56 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 2161 | 0.020 |
Why?
|
| Logistic Models | 1 | 2011 | 1841 | 0.020 |
Why?
|
| Brain | 1 | 2017 | 3194 | 0.010 |
Why?
|
| Pain Management | 1 | 2007 | 197 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2017 | 8548 | 0.010 |
Why?
|
| Pain | 1 | 2007 | 462 | 0.010 |
Why?
|
| Wounds and Injuries | 1 | 2007 | 394 | 0.010 |
Why?
|
| Mass Screening | 1 | 2009 | 830 | 0.010 |
Why?
|
| Texas | 1 | 2011 | 3632 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2011 | 17395 | 0.010 |
Why?
|
| Methylprednisolone | 1 | 2001 | 98 | 0.010 |
Why?
|
| Ultraviolet Rays | 1 | 2001 | 198 | 0.010 |
Why?
|
| Depression | 1 | 2009 | 1350 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 3995 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2007 | 7138 | 0.010 |
Why?
|
| Risk Factors | 1 | 2010 | 10945 | 0.010 |
Why?
|